<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39333316</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-024-03278-y</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are effective at protecting from severe disease, but the protective antibodies wane rapidly even though SARS-CoV-2-specific plasma cells can be found in the bone marrow (BM). Here, to explore this paradox, we enrolled 19 healthy adults at 2.5-33 months after receipt of a SARS-CoV-2 mRNA vaccine and measured influenza-, tetanus- or SARS-CoV-2-specific antibody-secreting cells (ASCs) in long-lived plasma cell (LLPC) and non-LLPC subsets within the BM. Only influenza- and tetanus-specific ASCs were readily detected in the LLPCs, whereas SARS-CoV-2 specificities were mostly absent. The ratios of non-LLPC:LLPC for influenza, tetanus and SARS-CoV-2 were 0.61, 0.44 and 29.07, respectively. In five patients with known PCR-proven history of recent infection and vaccination, SARS-CoV-2-specific ASCs were mostly absent from the LLPCs. We show similar results with measurement for secreted antibodies from BM ASC culture supernatant. While serum IgG titers specific for influenza and tetanus correlated with IgG LLPCs, serum IgG levels for SARS-CoV-2, which waned within 3-6 months after vaccination, were associated with IgG non-LLPCs. In all, our studies suggest that rapid waning of SARS-CoV-2-specific serum antibodies could be accounted for by the absence of BM LLPCs after these mRNA vaccines.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Doan C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0002-5389-6731</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hentenaar</LastName><ForeName>Ian T</ForeName><Initials>IT</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison-Porter</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solano</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-1348-3094</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castrillon</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Emory University, Atlanta, GA, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runnstrom</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Atlanta Veterans Affairs Healthcare System, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamothe</LastName><ForeName>Pedro A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-9262-2920</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonial</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4182-587X</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Emory University, Atlanta, GA, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>F Eun-Hyung</ForeName><Initials>FE</Initials><Identifier Source="ORCID">0000-0002-6133-5942</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, USA. f.e.lee@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA. f.e.lee@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AI172254</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>R01AI121252</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>1P01AI125180</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>U01AI141993</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>1P01AI125180</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>U54CA260563</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>1P01AI125180</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>INV-002351</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>T32HL116271</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country /></Grant><Grant><GrantID>T32HL116271</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Mar 05:2024.03.02.24303242. doi: 10.1101/2024.03.02.24303242</RefSource><PMID Version="1">38496525</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2024 Mar 13:rs.3.rs-3979237. doi: 10.21203/rs.3.rs-3979237/v1</RefSource><PMID Version="1">38559048</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333316</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-03278-y</ArticleId><ArticleId IdType="pii">10.1038/s41591-024-03278-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. WHO COVID-19 dashboard. https://covid19.who.int (2024).</Citation></Reference><Reference><Citation>Nguyen, D. C. et al. COVID-19 and plasma cells: is there long-lived protection? Immunol. Rev. 309, 40–63 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35801537</ArticleId><ArticleId IdType="pmc">9350162</ArticleId><ArticleId IdType="doi">10.1111/imr.13115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya, D. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity 55, 945–964 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35637104</ArticleId><ArticleId IdType="pmc">9085459</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado, N. &amp; Barouch, D. H. SARS-CoV-2 hybrid immunity: the best of both worlds. J. Infect. Dis. https://doi.org/10.1093/infdis/jiad353 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad353</ArticleId><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. C. et al. Plasma cell survival: the intrinsic drivers, migratory signals, and extrinsic regulators. Immunol. Rev. 303, 138–153 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34337772</ArticleId><ArticleId IdType="pmc">8387437</ArticleId><ArticleId IdType="doi">10.1111/imr.13013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. C. et al. Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture. Sci. Rep. 14, 3616 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38350990</ArticleId><ArticleId IdType="pmc">10864258</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-53977-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature https://doi.org/10.1038/s41586-021-03647-4 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId><ArticleId IdType="pubmed">34942634</ArticleId><ArticleId IdType="pmc">8850198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature 604, 141–145 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35168246</ArticleId><ArticleId IdType="pmc">9204750</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakaran, M. et al. Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates. Sci. Transl. Med. 16, eadd5960 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38170789</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.add5960</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19<sup>−</sup>CD38<sup>hi</sup>CD138<sup>+</sup> subset in human bone marrow. Immunity 43, 132–145 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26187412</ArticleId><ArticleId IdType="pmc">4680845</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2015.06.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner, C. J. et al. Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting. Life Sci. Alliance https://doi.org/10.26508/lsa.202101285 (2022).</Citation></Reference><Reference><Citation>Duan, M. et al. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep. 42, 112682 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37355988</ArticleId><ArticleId IdType="pmc">10391632</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2023.112682</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X., Yao, J., Zhao, Y., Wang, J. &amp; Qi, H. Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nat. Immunol. 23, 1564–1576 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36316480</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01345-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, M. J. et al. Intrinsically determined turnover underlies broad heterogeneity in plasma-cell lifespan. Immunity 56, 1596–1612 e1594 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37164016</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2023.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei, H. E. et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 125, 1739–1748 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25573986</ArticleId><ArticleId IdType="doi">10.1182/blood-2014-02-555169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. C. et al. Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. Nat. Commun. 9, 3698 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30209264</ArticleId><ArticleId IdType="pmc">6135805</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05853-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. C., Joyner, C. J., Sanz, I. &amp; Lee, F. E. Factors affecting early antibody secreting cell maturation into long-lived plasma cells. Front. Immunol. 10, 2138 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31572364</ArticleId><ArticleId IdType="pmc">6749102</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.02138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellier, J. &amp; Nutt, S. L. The secret to longevity, plasma cell style. Nat. Immunol. 23, 1507–1508 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36316478</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01340-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanna, I. J., Carlson, N. E. &amp; Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17989383</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa066092</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30837674</ArticleId><ArticleId IdType="doi">10.1038/s41577-019-0143-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Halasa, N. B., Gerber, M. A., Chen, Q., Wright, P. F. &amp; Edwards, K. M. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J. Infect. Dis. 197, 1448–1454 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18444800</ArticleId><ArticleId IdType="doi">10.1086/587643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodewes, R. et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin. Vaccin. Immunol. 18, 469–476 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00396-10</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharski, A. J. et al. Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol. 13, e1002082 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25734701</ArticleId><ArticleId IdType="pmc">4348415</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.1002082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945–1952 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0906453</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz, J. et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly Rep. 58, 521–524 (2009).</Citation></Reference><Reference><Citation>Skountzou, I. et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J. Immunol. 185, 1642–1649 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20585035</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1000091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisman, D. N. et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N. Engl. J. Med. 361, 2000–2001 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19907052</ArticleId><ArticleId IdType="doi">10.1056/NEJMc0907256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464–473 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28192418</ArticleId><ArticleId IdType="pmc">5360498</ArticleId><ArticleId IdType="doi">10.1038/ni.3684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, X. et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455, 532–536 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18716625</ArticleId><ArticleId IdType="pmc">2848880</ArticleId><ArticleId IdType="doi">10.1038/nature07231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667–671 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18449194</ArticleId><ArticleId IdType="pmc">2515609</ArticleId><ArticleId IdType="doi">10.1038/nature06890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, F. E. et al. Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. J. Immunol. 186, 5514–5521 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21441455</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1002932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId><ArticleId IdType="pmc">7164637</ArticleId><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId></ArticleIdList></Reference><Reference><Citation>Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614–1621 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15507523</ArticleId><ArticleId IdType="doi">10.1182/blood-2004-07-2507</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad, N. S. et al. One-stop serum assay identifies COVID-19 disease severity and vaccination responses. Immunohorizons 5, 322–335 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34001652</ArticleId><ArticleId IdType="doi">10.4049/immunohorizons.2100011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellier, J. et al. Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat. Immunol. 17, 323–330 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26779600</ArticleId><ArticleId IdType="pmc">4757736</ArticleId><ArticleId IdType="doi">10.1038/ni.3348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo, N. et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat. Immunol. 14, 298–305 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23354484</ArticleId><ArticleId IdType="doi">10.1038/ni.2524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, W. Y. et al. Metabolic and transcriptional modules independently diversify plasma cell lifespan and function. Cell Rep. 24, 2479–2492 e2476 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30157439</ArticleId><ArticleId IdType="pmc">6172041</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.07.084</ArticleId></ArticleIdList></Reference><Reference><Citation>Palm, A. E. &amp; Henry, C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front. Immunol. 10, 1787 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31417562</ArticleId><ArticleId IdType="pmc">6685390</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01787</ArticleId></ArticleIdList></Reference><Reference><Citation>Nellore, A. et al. A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. Immunity 56, 847–863 e848 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36958335</ArticleId><ArticleId IdType="pmc">10113805</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2023.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>White, E. M. et al. Asymptomatic and presymptomatic severe acute respiratory syndrome coronavirus 2 infection rates in a multistate sample of skilled nursing facilities. JAMA Intern. Med. 180, 1709–1711 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33074318</ArticleId><ArticleId IdType="pmc">7573793</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2020.5664</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, W. et al. Percentage of asymptomatic infections among SARS-CoV-2 Omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines https://doi.org/10.3390/vaccines10071049 (2022).</Citation></Reference><Reference><Citation>El-Ghitany, E. M. et al. Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study. Trop. Med Health 50, 98 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36575501</ArticleId><ArticleId IdType="pmc">9792933</ArticleId><ArticleId IdType="doi">10.1186/s41182-022-00490-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett, N. et al. High asymptomatic carriage with the omicron variant in South Africa. Clin. Infect. Dis. 75, e289–e292 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35353885</ArticleId><ArticleId IdType="pmc">9383623</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac237</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen, P. A. et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am. J. Pathol. 192, 642–652 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35123975</ArticleId><ArticleId IdType="pmc">8812084</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2022.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran, D. P. &amp; Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann. Intern. Med. 173, 362–367 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32491919</ArticleId><ArticleId IdType="doi">10.7326/M20-3012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehrani, Z. R. et al. Deficient generation of spike-specific long-lived plasma cells in the bone marrow after severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiad603 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad603</ArticleId><ArticleId IdType="pubmed">39052732</ArticleId><ArticleId IdType="pmc">11272043</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz, A. R. et al. SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow. EBioMedicine 95, 104735 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37556944</ArticleId><ArticleId IdType="pmc">10432952</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mujtahedi, S. S. et al. Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture. Transpl. Immunol. 75, 101726 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36183942</ArticleId><ArticleId IdType="doi">10.1016/j.trim.2022.101726</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellat-Deceunynck, C. &amp; Bataille, R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol. Dis. 32, 293–301 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15003821</ArticleId><ArticleId IdType="doi">10.1016/j.bcmd.2003.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann, M. F., Mohsen, M. O., Zha, L., Vogel, M. &amp; Speiser, D. E. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines 6, 2 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33398006</ArticleId><ArticleId IdType="pmc">7782831</ArticleId><ArticleId IdType="doi">10.1038/s41541-020-00264-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka, M. K. &amp; Amanna, I. J. Role of multivalency and antigenic threshold in generating protective antibody responses. Front. Immunol. 10, 956 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31118935</ArticleId><ArticleId IdType="pmc">6504826</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.00956</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff, M. C. et al. Response under pressure: deploying emerging technologies to understand B-cell-mediated immunity in COVID-19. Nat. Methods 19, 387–391 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35396475</ArticleId><ArticleId IdType="pmc">9703369</ArticleId><ArticleId IdType="doi">10.1038/s41592-022-01450-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad, N. S. et al. Circulating antibody-secreting cells are a biomarker for early diagnosis in patients with Lyme disease. PLoS ONE 18, e0293203 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37922270</ArticleId><ArticleId IdType="pmc">10624293</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0293203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>